Pancreatic Cancer Research

ResearcherTokyo Medical UniversityNo recent work listed

Koichi Tomita

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2484-6548; OpenAlex author ID A5085432516. Sources: OpenAlex.

Their work

Papers
4
Trials
0
Grants
0
Labs led
0
Collaborators
4
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 2 papers · 2021: none · 2022: 1 paper

Papers 4

  1. HOXB9 mediates resistance to chemotherapy and patient outcomes through the TGFβ pathway in pancreatic cancer. Co-author DOI 10.18632/oncotarget.28235↗
  2. Prognostic Significance of Plasma Fibrinogen/Serum Albumin Ratio in the Postoperative Outcome of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.21873/anticanres.14727↗
  3. Overexpression of hydroxyproline via EGLN/HIF1A is associated with distant metastasis in pancreatic cancer. Co-author PMID 32905516↗
  4. [The Efficacy of Neoadjuvant Chemoradiation Therapy for Borderline Resectable Pancreatic Cancer]. Co-author PMID 26805072↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Toru Sano · 4 shared papers, 2015–2022 · strength 0.44
  2. Shigeyuki Kawachi · 4 shared papers, 2015–2022 · strength 0.44
  3. Naokazu Chiba · 4 shared papers, 2015–2022 · strength 0.44
  4. Makoto Sunamura · 1 shared paper, 2020 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.